Acorda Therapeutics (NASDAQ:ACOR) Lowered to Strong Sell at BidaskClub

BidaskClub lowered shares of Acorda Therapeutics (NASDAQ:ACOR) from a sell rating to a strong sell rating in a report released on Tuesday morning, BidAskClub reports.

Other analysts also recently issued reports about the company. Wedbush set a $190.00 price objective on Home Depot and gave the stock a hold rating in a report on Wednesday, May 22nd. ValuEngine downgraded Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. JPMorgan Chase & Co. restated a sell rating and set a $60.00 price objective on shares of Bayerische Motoren Werke in a report on Tuesday, May 7th. Zacks Investment Research upgraded HB Fuller from a sell rating to a hold rating in a report on Wednesday, July 3rd. Finally, Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the stock a buy rating in a report on Tuesday, March 19th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $19.03.

ACOR stock opened at $6.62 on Tuesday. The firm has a market cap of $318.62 million, a P/E ratio of 3.64 and a beta of 1.15. The company has a current ratio of 4.30, a quick ratio of 3.97 and a debt-to-equity ratio of 0.66. The business’s fifty day moving average price is $8.01. Acorda Therapeutics has a 52 week low of $6.57 and a 52 week high of $30.25.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.51. The business had revenue of $44.14 million during the quarter, compared to the consensus estimate of $35.14 million. Acorda Therapeutics had a positive return on equity of 9.34% and a negative net margin of 1.40%. The business’s revenue for the quarter was down 58.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.14 EPS. As a group, equities analysts forecast that Acorda Therapeutics will post -4.11 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the company. Financial Gravity Wealth Inc. acquired a new stake in shares of Acorda Therapeutics during the first quarter valued at about $44,000. Oppenheimer Asset Management Inc. grew its stake in shares of Acorda Therapeutics by 45.8% during the first quarter. Oppenheimer Asset Management Inc. now owns 4,106 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,289 shares in the last quarter. NumerixS Investment Technologies Inc acquired a new stake in shares of Acorda Therapeutics during the fourth quarter valued at about $77,000. Piedmont Investment Advisors Inc. acquired a new stake in shares of Acorda Therapeutics during the first quarter valued at about $134,000. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Acorda Therapeutics by 869.8% during the first quarter. BNP Paribas Arbitrage SA now owns 10,241 shares of the biopharmaceutical company’s stock valued at $136,000 after acquiring an additional 9,185 shares in the last quarter.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.